Technology and Science15 September, 20263 min read
Evvy Raises $40M Series B Led by Catalio Capital Management for Women’s Health Precision Medicine
This article is an automated aggregation of coverage from news outlets. Our editorials offer in-depth analysis curated by the NewsCord team.
Oversubscribed $40M Series B led by Catalio Capital Management to scale AI-powered vaginal health platform. At-home vaginal health test with clinician-reviewed results and personalized treatment plans; expansion begins with fertility.
6 outlets told this the same way.
Evvy’s $40M Series B
Evvy, a NYC-based provider of a precision medicine platform for women’s health, raised $40M in Series B funding led by Catalio Capital Management, with participation from Rethink Impact, Muse Capital, Alumni Ventures, LabCorp Venture Fund, General Catalyst, Left Lane Capital, BBG Ventures, Amboy Street Ventures, Ingeborg, Foreground Capital, and Flywheel Ventures. The company said it intends to use the funds to validate new AI-driven diagnostic and care models across women’s health conditions, starting with fertility, and to expand distribution through physician and partner channels. Evvy’s platform is built around a clinical-grade dataset on the vaginal microbiome and its machine learning engine, EvvyAI, and it offers at-home metagenomic sequencing testing.
FinSMEs said Evvy serves over 100,000 patients and 3,000 practitioners, and that each test is clinician-led interpretation with longitudinal biomarker tracking. Pulse 2.0 similarly reported the oversubscribed $40 million Series B and said Evvy’s platform now serves more than 100,000 patients and 3,000 healthcare practitioners through at-home testing, personalized treatment and longitudinal biomarker tracking.
AI, metagenomic testing, outcomes
Evvy’s at-home testing is described as CLIA-certified and New York State CLEP-approved metagenomic sequencing, with results ordered and interpreted by licensed clinicians, and where appropriate paired with prescription treatment pathways. Pulse 2.0 said Evvy’s research platform has contributed to 13 peer-reviewed publications and abstracts, helped identify novel bacterial vaginosis subtypes, and uncovered hundreds of previously uncatalogued vaginal microbiome genomes. The company also tied its approach to performance claims, saying licensed clinicians using its platform and EvvyAI have been able to provide a diagnosis to more than 90% of symptomatic patients and achieve an approximately 50% reduction in bacterial vaginosis recurrence through targeted treatment protocols.
TechCrunch reported that when a patient receives their results, they are presented alongside a diagnosis, clinical interpretation, and a clear path of next steps, including personalized prescription care when relevant. TechCrunch added that EvvyAI is an AI assistant launched in May that translates microbiome data into real-time guidance for users and directs patients to clinicians for questions that need expert opinions.
Fertility focus and broader stakes
Evvy’s expansion plan centers on fertility first, with Pulse 2.0 saying the Series B will fund clinical validation of additional EvvyAI-powered diagnostic and care models across women’s health, beginning with fertility. SiliconANGLE reported that Evvy’s co-founder and Chief Executive Priyanka Jain said the biological signals unique to female bodies have been overlooked by most medical researchers, and that women face misdiagnosis rates higher than 50% for some conditions and recurrence rates of more than 60% for common vaginal symptoms. SiliconANGLE also quoted Jain saying, “Women hear ‘unexplained’ constantly, whether it’s unexplained infertility, unexplained recurrence, unexplained pain,” and added that it’s “stated like a diagnosis, when it really means medicine wasn’t built to measure female biology.”
Fierce Healthcare reported Jain’s view that “I do not want to wait for the government to fund women’s health research and especially vagina research,” and said Evvy has led a fertility study in partnership with US Fertility with findings to be published later this year. TechCrunch framed the longer-term goal as building a dataset that connects microbiome biology, symptoms, interventions, and health outcomes, with Jain describing it as “creating a continuous feedback loop that unlocks improvements to care and the discovery of entirely new biomarkers.”